{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:20:49Z","timestamp":1771266049188,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002329","name":"Bundesamt f\u00fcr Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-023-01211-3","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T04:28:45Z","timestamp":1673324925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The clinical effectiveness of denosumab (Prolia\u00ae) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"18","author":[{"given":"Konstance","family":"Nicolopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena Ruth","family":"Moshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Jenal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vreugdenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6:901\u2013910","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"BMT40","DOI":"10.2217\/bmt-2020-0012","volume":"9","author":"CL Shapiro","year":"2020","unstructured":"Shapiro CL (2020) Management of osteoporosis in women with breast cancer. Breast Cancer Management 9:BMT40","journal-title":"Breast Cancer Management"},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238\u2013244","journal-title":"JAMA"},{"issue":"Suppl 2","key":"1211_CR4","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/8756-3282(92)90192-Y","volume":"13","author":"RP Heaney","year":"1992","unstructured":"Heaney RP (1992) The natural history of vertebral osteoporosis. Is low bone mass an epiphenomenon. Bone 13(Suppl 2):S23-26","journal-title":"Bone"},{"key":"1211_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jbmr.5650050302","volume":"5","author":"JA Kanis","year":"1990","unstructured":"Kanis JA (1990) Osteoporosis and osteopenia. J Bone Min Res: Off J Am Soc Bone Min Res 5:209\u2013211","journal-title":"J Bone Min Res: Off J Am Soc Bone Min Res"},{"key":"1211_CR6","unstructured":"Ganesan K, Jandu JS, Roane D (2022) Secondary osteoporosis. StatPearls. StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC., Treasure Island (FL)"},{"key":"1211_CR7","unstructured":"International Osteoporosis Foundation (2022) About. International Osteoporosis Foundation. https:\/\/www.osteoporosis.foundation\/health-professionals\/about-osteoporosis Accessed 14 March 2022"},{"key":"1211_CR8","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/EJE-15-0118","volume":"173","author":"F Mirza","year":"2015","unstructured":"Mirza F, Canalis E (2015) Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 173:R131\u2013R151","journal-title":"Eur J Endocrinol"},{"key":"1211_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13058-018-1061-4","volume":"20","author":"C Ramin","year":"2018","unstructured":"Ramin C, May BJ, Roden RBS, Orellana MM, Hogan BC, McCullough MS, Petry D, Armstrong DK, Visvanathan K (2018) Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study. Breast Cancer Res 20:134","journal-title":"Breast Cancer Res"},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7 (2017) An overview and management of osteoporosis. Eur J Rheumatol 4:46\u201356","journal-title":"Eur J Rheumatol"},{"key":"1211_CR11","unstructured":"Bundesamt f\u00fcr Gesundheit (2021) Spezialit\u00e4tenliste. http:\/\/www.spezialitaetenliste.ch\/Default.aspx Accessed 24 May 2021 2021"},{"key":"1211_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1759720X18805759","volume":"10","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM (2018) New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Therapeutic Adv Musculoskeletal Dis 10:209\u2013223","journal-title":"Therapeutic Adv Musculoskeletal Dis"},{"key":"1211_CR13","unstructured":"United Nations Department of Economic and Social Affairs (UN DESA), United Nations Conference on Trade and Development (UNCTAD), Economic Commission for Africa (UNECA), Economic Commission for Europe (UNECE), Economic Commission for Latin America and the Caribbean (UNECLAC) EaSCfAatPU, Economic and Social Commission for Western Asia (UNESCWA), report. UNWTOUactt (2022) World Economic Situation and Prospects 2022. United Nations,"},{"key":"1211_CR14","first-page":"81","volume":"14","author":"F Livio","year":"2018","unstructured":"Livio F (2018) Pharmacovigilance update. Rev Med Suisse 14:81\u201384","journal-title":"Rev Med Suisse"},{"key":"1211_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 6:e1000097","journal-title":"PLoS medicine"},{"key":"1211_CR16","unstructured":"Canadian Agency for Drugs and Technologies in Health (2019) Strings Attached: CADTH's Database search filters. Canadian Agency for Drugs and Technologies in Health. https:\/\/www.cadth.ca\/resources\/finding-evidence\/strings-attached-cadths-database-search-filters Accessed January 05 2021"},{"key":"1211_CR17","unstructured":"World Health Organization (2020) List of member states by WHO region and mortality stratum. World Health Organization. https:\/\/www.who.int\/choice\/demography\/mortality_strata\/en\/ Accessed February 5 2020"},{"key":"1211_CR18","unstructured":"Ankit Rohatgi (2020) WebPlotDigitizer. Ankit Rohatgi. https:\/\/automeris.io\/WebPlotDigitizer\/ Accessed Febuary 8 2020"},{"key":"1211_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"1211_CR20","unstructured":"R Core Team (2020) R: a language and environment for statistical computing. Foundation for Statistical Computing, Vienna, Austria"},{"key":"1211_CR21","unstructured":"RStudio Team (2020) RStudio: integrated development for R. RStudio, Boston, USA"},{"key":"1211_CR22","unstructured":"Schwarzer G (2021) General package for meta-analysis. Version 4.18\u20130. https:\/\/cran.r-project.org\/web\/packages\/meta\/meta.pdf"},{"key":"1211_CR23","unstructured":"Schwarzer G (2021) Package \u2018netmeta\u2019 reference manual. https:\/\/cran.r-project.org\/web\/packages\/netmeta\/netmeta.pdf April 2021"},{"key":"1211_CR24","doi-asserted-by":"crossref","unstructured":"Schwarzer G, Carpenter J, R\u00fccker G (2015) Meta-analysis with R","DOI":"10.1007\/978-3-319-21416-0"},{"key":"1211_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58","journal-title":"BMC Med Res Methodol"},{"key":"1211_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T (2017) Network meta-analysis: an introduction for clinicians. Intern Emerg Med 12:103\u2013111","journal-title":"Intern Emerg Med"},{"key":"1211_CR27","doi-asserted-by":"crossref","unstructured":"Higgins JPT J, Chandler J, Cumpston M, Li T, Page M.J, Welch V.A. (editors) (2020) Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Cochrane","DOI":"10.1002\/9781119536604"},{"key":"1211_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","volume":"13","author":"U Krahn","year":"2013","unstructured":"Krahn U, Binder H, K\u00f6nig J (2013) A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 13:35","journal-title":"BMC Med Res Methodol"},{"key":"1211_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring Inconsistency Meta-analyses. BMJ (Clin Res ed) 327:557\u2013560","journal-title":"Measuring Inconsistency Meta-analyses. BMJ (Clin Res ed)"},{"key":"1211_CR30","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V (2020) Cochrane handbook for systematic reviews of interventions version 6.1. Cochrane. www.training.cochrane.org\/handbook Accessed September 2020","DOI":"10.1002\/9781119536604"},{"key":"1211_CR31","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLOS ONE 8:e76654","journal-title":"PLOS ONE"},{"key":"1211_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G (2012) Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synthesis Methods 3:161\u2013176","journal-title":"Res Synthesis Methods"},{"key":"1211_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. J N Engl J Med 361:745\u2013755","journal-title":"J N Engl J Med"},{"key":"1211_CR34","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol 25:1038\u20131042","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1211_CR35","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","volume":"85","author":"R Choo","year":"2013","unstructured":"Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C (2013) Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiation Oncol, Biol, Phys 85:1239\u20131245","journal-title":"Int J Radiation Oncol, Biol, Phys"},{"key":"1211_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146:416\u2013424","journal-title":"Ann Intern Med"},{"key":"1211_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","volume":"5","author":"RS Israeli","year":"2007","unstructured":"Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV (2007) The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 5:271\u2013277","journal-title":"Clin Genitourin Cancer"},{"key":"1211_CR38","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","volume":"182","author":"N Bhoopalam","year":"2009","unstructured":"Bhoopalam N, Campbell SC, Moritz T et al (2009) Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 182:2257\u20132264","journal-title":"J Urol"},{"key":"1211_CR39","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/jbmr.4106","volume":"35","author":"AS Cheung","year":"2020","unstructured":"Cheung AS, Hoermann R, Ghasem-Zadeh A, Tinson AJ, Ly V, Milevski SV, Joon DL, Zajac JD, Seeman E, Grossmann M (2020) Differing effects of zoledronic acid on bone microarchitecture and bone mineral density in men receiving androgen deprivation therapy: a randomized controlled trial. J Bone Mineral Res\u202f: Off J Am Soc Bone Min Res 35:1871\u20131880","journal-title":"J Bone Mineral Res : Off J Am Soc Bone Min Res"},{"key":"1211_CR40","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"LH Klotz","year":"2013","unstructured":"Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research C (2013) A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol 63:927\u2013935","journal-title":"Eur Urol"},{"key":"1211_CR41","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","volume":"176","author":"CW Ryan","year":"2006","unstructured":"Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176:972\u2013978","journal-title":"J Urol"},{"key":"1211_CR42","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008\u20132012","journal-title":"J Urol"},{"key":"1211_CR43","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 26:4875\u20134882","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1211_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 386:433\u2013443","journal-title":"Lancet (London, England)"},{"key":"1211_CR45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger GG et al (2019) Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:339\u2013351","journal-title":"Lancet Oncol"},{"key":"1211_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1210\/jc.2006-1272","volume":"92","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bhattacharya RK, Sereika SM, Brufsky A, Vogel VG (2007) Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metabolism 92:131\u2013136","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1211_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2018.12.005","volume":"108","author":"L Livi","year":"2019","unstructured":"Livi L, Scotti V, Desideri I et al (2019) Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer 108:100\u2013110","journal-title":"Eur J Cancer"},{"key":"1211_CR48","unstructured":"European Medicines Agency (2006) Committee for medicinal products for human use (CHMP): guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf Accessed 21 July 2021"},{"key":"1211_CR49","first-page":"413","volume":"28","author":"A Cranney","year":"2001","unstructured":"Cranney A, Welch V, Wells G, Adachi J, Shea B, Simon L, Tugwell P (2001) Discrimination of changes in osteoporosis outcomes. J Rheumatol 28:413\u2013421","journal-title":"J Rheumatol"},{"key":"1211_CR50","first-page":"9","volume":"9","author":"J Guralnik","year":"2020","unstructured":"Guralnik J, Bandeen-Roche K, Bhasin SAR, Eremenco S, Landi F, Muscedere J, Perera S, Reginster JY, Woodhouse L, Vellas B (2020) Clinically meaningful change for physical performance: perspectives of the ICFSR task force. J Frailty Aging 9:9\u201313","journal-title":"J Frailty Aging"},{"key":"1211_CR51","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 130:115081","journal-title":"Bone"},{"key":"1211_CR52","first-page":"f2914","volume":"346","author":"E Mills","year":"2013","unstructured":"Mills E, Thorlund K, Ioannidis J (2013) Demystifying trial networks and network meta-analysis. BMJ (Clinical research ed) 346:f2914","journal-title":"BMJ (Clinical research ed)"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01211-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-023-01211-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01211-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:25:15Z","timestamp":1704374715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-023-01211-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1007\/s11657-023-01211-3","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"18"}}